Genolution Launches Global NGS-Based Human Papillomavirus Analysis Platform

[Asia Economy Reporter Hyunseok Yoo] Genolution, a company specializing in in vitro diagnostic devices, announced on the 22nd that it has newly launched an NGS-based HPV analysis platform (GYNseq HPV 100 typing NGS Kit).

NGS (Next Generation Sequencing) is a technology that cuts the genome into small pieces, converts the nucleotide sequences of each fragment into data, and is known as next-generation sequencing. It enables highly precise diagnostics and is gaining attention as a personalized treatment method for patients.

The newly launched NGS-based HPV analysis platform by Genolution offers advantages such as faster, simpler processing and the ability to handle a large number of samples simultaneously. It can distinguish over 100 types of HPV at once, making it the most accurate next-generation testing method expected to replace existing testing methods.

A Genolution official stated, "While global demand for our existing core products, nucleic acid extraction equipment and reagents, continues to expand, the addition of this new NGS-based product creates opportunities for new sales. With the launch of products based on the precise NGS technology, we expect to meet the diverse needs of global customers, leading to expanded client base and increased sales."

The success of this new product development was achieved through an ODM business partnership with SML Genetree, which is currently the most notable company in the market, based on Genolution’s global competitiveness in in vitro diagnostic devices and SML Genetree’s world-class diagnostic device development capabilities.

SML Genetree is the world’s first company to develop HPV NGS and the only company in Korea to have received approval for an NGS-based diagnostic kit. Genolution has proven its technological capabilities with in vitro diagnostic devices responding to the novel coronavirus infection (COVID-19). The automatic nucleic acid extraction equipment (Nextractor® NX-48) brand also has established global recognition, so the company expects a rapid effect from the new product launch.

Genolution generates over 80% of its sales overseas, reflecting its high global recognition. This is based on years of experience with equipment and reagents for nucleic acid extraction, a core process in molecular diagnostics, and a close network with more than 40 distributors across Europe, Asia, and North and South America, as well as major domestic and international institutions and local distributors. Furthermore, Genolution’s long-established diagnostic device business capabilities, combined with product diversification applying new technologies, are expected to enable expansion into new markets.

Kim Ki-ok, CEO of Genolution, said, "Genolution is responding rapidly to the global situation amid COVID-19. Based on the closely built network, we will strive to achieve up to a 10% global market share by 2027 through the launch of this NGS-based analysis platform, which will bring innovation to the HPV diagnostic testing market."

This content was produced with the assistance of AI translation services.